Atossa Genetics, Inc. (NASDAQ:ATOS) Gaps Up Before the Earnings Release

[[tagnumber 0]]Atossa Genetics, Inc. (NASDAQ:ATOS) is supposed to release its third quarter earning today, yet the report is not out yet and the stock opened with a gap yesterday on the expectation of the new information. The company‘s shares are trading under the threat of delisting from NASDAQ, thus any positive signs could make the stock gain more.[[tagnumber 1]] [[tagnumber 0]][[tagnumber 3]][[tagnumber 1]] [[tagnumber 0]]Yesterday, ATOS closed the market at $0.72 for a share which is an over 11% gain from the previous close. The trading volume was a few times higher than the average and overall the chart looks promising for the new session today. After the large gap up at market open, the share price broke up higher and crossed the 20–day moving average which is another bullish signal.[[tagnumber 1]] [[tagnumber 0]]ATOS has not released any updates on its business recently and the stock is following a long–term downtrend. The report for the second quarter shows a good cash position which came, however, at the cost of significant shareholder dilution. Though t[[tagnumber 8]]here are some revenues from the sale of the ForeCYTE Breast Aspirator and from related services, the main source of cash this year were equity offerings in which ATOS issued nearly 4 million new shares.[[tagnumber 1]] [[tagnumber 0]]In the beginning of October, the company received a notice of failure to comply with a NASDAQ listing requirement as ATOS stock had traded under $1 for more than a month. ATOS has time until March 2016 to regain compliance, yet the latest financial data does not suggest it could manage to do so.[[tagnumber 1]] [[tagnumber 0]]The company‘s leading product candidate for the treatment of breast disease is still in Phase II clinical trials. Management admits that it will need to conduct more stock offerings to raise the required cash. In the meantime, the company already has 9.6 million outstanding warrants to purchase shares of common stock, for 3.6 million of which the exercise price is only $0.01.[[tagnumber 1]] [[tagnumber 14]] [[tagnumber 1]]